FOXO CEO Seamus Lagan provided a comprehensive Year-End Review to shareholders, highlighting key milestones and the company's growth strategy for the future.
The review included updates on acquisitions such as Myrtle Recovery Centers, Rennova Community Health, and Vector BioSource.
FOXO demonstrated significant financial progress, settling legacy liabilities, strengthening equity, and reducing debt.
Acquisitions Boost Portfolio
The acquisitions of Myrtle Recovery Centers, Rennova Community Health, and Vector BioSource have expanded FOXO's healthcare-related businesses and positioned the company for growth.
Financial Performance
FOXO reported net revenues of approximately $12 million for the nine months ended September 30, 2025, with further growth expected to exceed $15 million for the full year ending December 31, 2025.
Debt Reduction and Equity Strengthening
FOXO successfully reduced debt from $10.2 million to $7.1 million and increased equity from $5.3 million to $20.2 million, showcasing financial stability and strength.
- The acquisitions of Myrtle Recovery Centers and Rennova Community Health have diversified FOXO's healthcare services, providing opportunities for growth and community impact.
- The addition of Vector BioSource positions FOXO as a key player in the pharmaceutical services sector, with projected net revenues of $1 million for 2025 and promising future growth prospects.
FOXO Technologies Inc. has made significant strides in 2025, expanding its portfolio and demonstrating financial resilience. The company's strategic acquisitions and financial progress set a positive trajectory for future growth and success in the healthcare and pharmaceutical sectors.